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Abstract
Antibodies to polymorphic antigens expressed during the parasites erythrocytic stages are important mediators of
protective immunity against P. falciparum malaria. Therefore, polymorphic blood stage antigens like MSP3, EBA-175 and
GLURP and variant surface antigens PfEMP1 and RIFIN are considered vaccine candidates. However, to what extent these
antibodies to blood stage antigens are acquired during naive individuals’ first infections has not been studied in depth.
Using plasma samples collected from controlled experimental P. falciparum infections we show that antibodies against
variant surface antigens, PfEMP1 and RIFIN as well as MSP3 and GLURP, are acquired during a single short low density P.
falciparum infection in non-immune individuals including strain transcendent PfEMP1 immune responses. These data
indicate that the immunogenicity of the variant surface antigens is similar to the less diverse merozoite antigens. The
acquisition of a broad and strain transcendent repertoire of PfEMP1 antibodies may reflect a parasite strategy of expressing
most or all PfEMP1 variants at liver release optimizing the likelihood of survival and establishment of chronic infections in
the new host.
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Introduction
Malaria caused by Plasmodium falciparum constitutes a major
burden to large parts of the world despite efforts to reduce
transmission and increase treatment. In malaria endemic
populations, immunity to malaria is acquired slowly as a function
of experienced infections. In regions with stable malaria
transmission immunity to uncomplicated malaria is not acquired
until adolescence [1] whereas protection against severe, non-
cerebral malaria and death is obtained after only a few infections
[2]. This development of immunity is thought to reflect the
gradual acquisition of effective cells and antibodies directed
against malaria polymorphic and variable P. falciparum blood
stage antigens [3–6]. Identification of these effective antibodies
may lead to a vaccine mimicking the natural acquired protection
against malaria. Identified polymorphic blood stage vaccine
candidates include merozoite surface protein 3 (MSP3), erythro-
cyte-binding antigen 175 (EBA-175) and glutamate-rich protein
(GLURP). MSP3 and EBA-175 are located on the extracellular
merozoite surface and are involved in red blood cell invasion
[7,8] while GLURP is expressed in both the pre-erythrocytic and
erythrocytic stage [9] but no function has yet been ascribed. Of
considerable interest are also the variant surface antigens
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1)
and RIFINs. PfEMP1 mediate adhesion to human endothelial
receptors [5,10–13] probably to avoid clearance by the spleen
[14] whereas the function of RIFINs is yet unknown, although it
is proposed that they expose their highly polymorphic V2 region
on the surface of infected erythrocytes and therefore contributing
to the antigenic variation of a P. falciparum infection [15,16].
PfEMP1 molecules are encoded by a repertoire of around 60
different var genes per genome but are generally thoutht to be
expressed one at a time [17,18], although the co-expression of
two different PfEMP1 variants has been observed in the
laboratory-cultured parasite clone 3D7 [19]. The extracellular
variable part of PfEMP1 contains an N-terminal segment
followed by segments composed of two main domain types,
Duffy binding-like domains (DBL) and cysteine-rich inter-domain
regions (CIDR), which can be further divided into classes and
sub-classes based on sequence similarity [20]. The var genes are
divided into four main groups (A, B, C and VAR2CSA), each
group shares specific 59 promoter regions and phylogenetically
distinct DBL and CIDR domains [20,21,22]. The VAR2CSA
PfEMP1 is involved in pregnancy malaria by facilitating parasite
sequestration in the placenta [13]. Moreover, immunological
studies imply that an antigenically conserved subset of PfEMP1
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Recently, it was shown that children living in areas of high P.
falciparum transmission gradually but most rapidly acquire a
broad anti-PfEMP1 antibody repertoire and antibodies against
DBL domains of the group A PfEMP1 variants are acquired
first [26]. Group A PfEMP1 have previously been associated
with severe childhood malaria by studies of both var expression
and PfEMP1 antibody acquisition [27–31]. Studies of var
expression in controlled experimental infections of naı ¨ve Dutch
individuals infected with the NF54 parasite strain (parental strain
of the 3D7 clone) have suggested that most of the different
parasites released from the liver cells express different var genes
and that continuous growth may favour parasite expressing
PfEMP1 variants facilitating the most effective sequestration to
host endothelium [32]. However, it has not been known if the
short period of infection (1–5 days or 1–3 post liver release
parasite life cycles) in experimentally infected volunteers and the
parasite densities obtained (low maximum parasitaemia ,44.000
parasites/ml) are sufficient to induce antibody responses to the
above mentioned bloodstage antigens. Therefore, plasma samples
collected from controlled malaria infections of naı ¨ve volunteers
[33–37] were used to investigate the acquisition of antibodies to
an array of 104 PfEMP1 domains, eight RIFINs, MSP3, EBA-
175, and GLURP.
Materials and Methods
Ethics statement
Informed consent form was signed by all subjects and the trials
were reviewed and approved by the Ethical Committee of the
Radboud University Nijmegen Medical Center (CWOM: 0004-
0090, 0011-0262, 2001/203, 2002/170, and 2004/129) and the
Central Committee for Research Involving Human Subjects of
The Netherlands (CCMO NL24193.091.09) as previously de-
scribed [33–38].
Experimental infections of human volunteers and plasma
samples
This study benefits from the plasma collected from naı ¨ve
volunteers infected with the Plasmodium falciparum NF54 isolate by
bites of Anopheles stephensi mosquitoes, and treated after a few
rounds of asexual parasite multiplication, when parasites could be
detected or the patient developed symptoms [33–37]. These
controlled human malaria infection (CHMI) experiments were
conducted in six series, between which the experimental set up
(number of infectious mosquito bites, day of treatment relative to
first detection of asexual parasitemia differed slightly (Table S1).
From these 44 volunteers blood samples were taken on the day
before infection and on day 21, day 21 and 42, day 21 and 90,
day 35, day 42, or day 90 post infection from 14, 11, 9, 5, 1, and
4 volunteers, respectively (Table S1). In addition, we analysed
plasma from 10 volunteers who had been immunized by
receiving three rounds of experimental infections under a
chloroquine prophylaxis and then challenged by a fourth
exposure to infectious mosquito bites without chloroquine cover
[37]. These individuals experienced brief asymptomatic very low
density asexual infections during the immunisation phase, but no
asexual parasitemia were detected during the challenge [37].
From these individuals plasma collected the day before exposure
to the bites of the infectious mosquitoes (days 0, 32, 60, 116 after
the initiation of the experiment)and on days 35 and 140 after the
challenge infection (days 151 and 256 after initiation of the
experiment) were available (Table S1). Plasma samples were
stored at 280uC.
Protein expression
Protein expression was as previously described [27,39]. In short,
primer pairs designed to contain restriction enzyme sites were used
to amplify var gene fragments encoding 104 PfEMP1 domains (67
DBL, 32 CIDR, 5 multi-domain constructs) representing four
different genetic backgrounds (see Table S2): 3D7/NF54: 39 DBL,
15 CIDR, 3 DBL-DBL and 2 DBL-CIDR; HB3: 13 DBL and 8
CIDR; IT/FCR3: 15 DBL and 8 CIDR; Dd2: 1 CIDR domain.
Primer pairs amplifying eight RIFIN V2 domains and the F2
region of EBA-175 from 3D7/NF54 genomic DNA were also used
(Table S2). The R0, R1, R2 (N-terminal non-repeat, central
repeat and C-terminal repeat regions of GLURP), and the C-
terminal region of MSP3 were included in the study as well
[40,41]. Digested PCR products were cloned into the Baculovirus
vector, pAcGP67-A (BD Bioscience) designed to contain the V5
epitope upstream of a histidine tag in the C-terminal end of the
constructs or in the case of the RIFINs a GST tag. Identity of the
cloned fragments was verified by sequencing. Linearized Bakpak6
Baculovirus DNA (BD Biosciences Clontech) was co-transfected
with pAcGP67-A into Sf9 insect cells for generation of
recombinant virus particles and histidine-tagged proteins secreted
into the supernatant of infected High-Five insect cell were purified
on Co2+ metal-chelate agarose columns. Eluted products were
dialysed overnight in PBS. The yield, integrity and purity of the
recombinant proteins were estimated by analysis on SDS gel,
comparing to BSA standards, and by western blotting using the
anti-V5 Ab. All of the proteins coupled to the Luminex beads were
estimated to be at or above 80% purity.
Covalent coupling of recombinant PfEMP1 proteins to
beads
Carboxylated Luminex microspheres were covalently coated
with the different protein domains through an interaction of their
carboxyl groups and the amino groups on the proteins following
the procedure suggested by the manufacturer. Microspheres
(1.25610
7 microspheres/ml) were brought to room temperature,
vortexed for 1 min, and transferred to Eppendorf tubes. The
supernatant was removed after centrifugation for 1 min at
16,000 x g. One millilitre of distilled water was added to the
microspheres, vortexed for re-suspension, followed by centrifuga-
tion for 1 min at 16,000 x g. The microspheres were sonicated in a
water bath sonicator into suspension and centrifuged for 1 min at
16,000 x g. The supernatant was removed and 1 ml of activation
buffer (0.1 M NaH2PO4 (pH 6.2)) was added to the pellet and
vortexed for re-suspension. In separate tubes 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and
N-hydroxysulfosuccinimide (Sulfo-NHS; Pierce Biotechnology)
were reconstituted to 50 mg/ml, and 125 ml of each was added
to the microspheres, vortexed, and incubated at room temperature
for 20 min with inversions in the dark. The microspheres were
centrifuged for 1 min at 16,000 x g, re-suspended in 1 ml of
50 mM MES (pH 5.0), centrifuged for 1 min at 16,000 x g, and
the supernatant was removed. The MES wash was repeated. The
microspheres were re-suspended in 500 ml of MES. In separate
tubes, the different protein samples (100 mg per ml of micro-
spheres) were mixed with MES to a final volume of 500 ml and
each was added to a separate microsphere population and
incubated at room temperature for 2 h in the dark with inversions.
The microspheres were centrifuged for 1 min at 16,000 x g and
the supernatant was removed. The microspheres were washed
twice in 1 ml of PBS/TBN (0.02% Tween 20, 0.1% BSA, and
0.05% sodium azide in PBS (pH 7.4)). The microspheres were re-
suspended in 1 ml of PBS/TBN and stored at 4uC in the dark. To
determine whether coupling was effective, aliquots of the different
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and analyzed on the Luminex instrument.
Multiplexing and lyophilization of microspheres
Equal volumes of the coated microspheres were pooled together
and mixed by vortexing. Sucrose and Tween 20 were added to 3%
and 0.05%, respectively, mixed by vortexing, and single-use
aliquots were lyophilized (AdVantage, Wizard 2.0; VirTis) in
polypropylene vials, sealed under nitrogen gas, and stored at
280uC. Immediately before use, lyophilized microspheres were
reconstituted with distilled water and used for analysis [43] as
described below.
Analysis of coupled microspheres on the Luminex
The coated microspheres were diluted 1/333 in assay buffer E
(ABE buffer, 0.1% BSA, 0.05% Tween 20, 0.05% sodium azide in
PBS (pH 7.4)) and 50-ml aliquots were dispensed into the wells of a
1.2-mm filter bottom 96-well microtiter plate (MSBVS 1210;
Millipore) pre-wetted with ABE buffer. The microspheres in 96-
well plates were washed three times with ABE using a vacuum
manifold (Millipore). Frozen plasma samples were thawed at room
temperature, mixed by vortexing, and spun at 16,000 x g for
5 min to remove particulates. Plasma samples were diluted 1/80
in ABE buffer and 50-ml aliquots of diluted sample were added to
the microspheres and incubated in the dark on a shaking platform
at 1100 rpm for 30 s followed by 300 rpm for 30 min. Excess
antibody was removed using a vacuum manifold followed by three
washes in ABE. 25 ml of biotinylated human IgG (Sigma-Aldrich)
detection antibody diluted 1/500 in ABE was added to the
microspheres, incubated in the dark with shaking at 1100 rpm for
30 s, followed by 300 rpm for 30 min and washed three times in
ABE. 50 ml of streptavidin-PE (Sigma-Aldrich) diluted 1/500 in
ABE was added to the microspheres and incubated in the dark
with shaking at 1100 rpm for 30 s, followed by 300 rpm for
10 min. Excess streptavidin-PE was removed followed by three
washes in ABE. The microspheres were then re-suspended in
125 ml of ABE and analyzed on the Luminex instrument. The
reader was set to read a minimum of 100 microspheres per
microsphere region and results were expressed as median
fluorescent intensity.
Statistical analyses
The purpose of the study was to determine to which degree the
volunteer’s acquired antibodies to the tested malaria antigens. To
this end the reactivity (measured in MFI) in the sample collected
from each individual prior to malaria exposure was used as a
baseline. Individuals were defined as having acquired an IgG
response if the MFI in the sample collected during the
experiment/MFI in the sample collected at the beginning of
the experiment was .3 and the MFI in the sample collected
during the experiment was .500. This conservative cut-off
definition was used to assure that responder status not reflected
general increases in IgG levels or small variations in background
levels. To compare acquisition of antibodies between those who
were experimentally infected and those who were protected by
repeated immunisations before challenge we used Wilcoxon rank-
sum test for unpaired data to compare the number of PfEMP1
domains to which antibodies were acquired. Relations between
acquisition of PfEMP1 antibodies and parasite load, maximum
parasitemia, number of mosquito bites and number of asexual
cycles completed before treatment was done using Spearman’s
rank sum test. Stata 12 (http://www.stata.com/stata12/) was
used for the analyses.
Results
Acquisition of IgG to GLURP, MSP3, and EBA-175
Antibody levels to N-terminal, Central and C-terminal repeat
regions (R0, R1 and R2) of GLURP, C-terminal region of MSP3
and the N-terminal F2 region of EBA-175 were measured in
plasma collected from 44 naı ¨ve Dutch volunteers before and after
a controlled human malaria infection with Plasmodium falciparum
isolate NF54 which is a relatively short infection period. Around
70% of the volunteers acquired IgG against R2 whereas IgG to R0
and R1 only were acquired by approximately 13% (Figure 1). IgG
with specificity to MSP3 was acquired by , 10%. None of the
volunteers acquired IgG antibodies to EBA-175 (Figure 1).
Acquisition of anti-PfEMP1and anti-RIFIN IgG
IgG reactivity to 104 recombinant PfEMP1 domains amplified
from 3D7/NF54, HB3, IT/FCR3 and Dd2 genomes were
measured in plasma samples from the same 44 individuals before
and after P. falciparium infection. Of those 104 domains, 79 were
recognized by between 3 and 12% of the volunteers (Figure 2) with
no clear distinction in the recognition of domains according to
domain subclass or PfEMP1 group. The pattern of antibody
acquisition varied considerably among the 44 volunteers, but
could be divided into six groups represented by their acquisition
pattern (Figure 3). The 44 volunteers were grouped into
individuals who did not acquire antibodies to any of the malaria
antigens (n=3; 7%), individuals who acquired antibodies to
GLURP only (n=11; 25%), and individuals who acquired
antibodies to 1, 2, 3 or .3 PfEMP1 domains as well as to one
or more of the merozoite antigens (n=12, 5, 4 and 9; in total
,68%). 41% of the 44 volunteers responded to a non-NF54
PfEMP1 domains and of the 45 PfEMP1 domains amplified from
P. falciparum HB3, IT/FCR3 and Dd2 genomic DNA, 31 were
recognized (Figure 2). The pattern of antibody acquisition did not
correlate with the parasite load, maximum parasitemia, number of
mosquito bites or number of intra-erythrocytic parasite cycles.
Antibody levels to the extracellular polymorphic domain [15], V2,
of eight recombinant RIFIN proteins were also tested. Six
volunteer acquired antibodies to in total four of the eight RIFINs
(Figure 4).
Acquisition of antibodies to blood stage antigens during
an immunization study
During an immunization study at Radboud University,
Nijmegen [37], 10 volunteers were immunized by NF54 parasites
by the bites of infectious mosquitoes three times with an interval of
Figure 1. Proportion of malaria naı ¨ve volunteers acquiring IgG
against GLURP, MSP3 and EBA175 antigens after controlled
experimental P. falciparum infections. The percentage of malaria
infected volunteers with a measurable IgG response against GLURP R0,
R1, R2, MSP3 and EBA175 malaria antigens on day 21 (N=34) and/or
day 35, 42 or 90 (N=30) post infection in descending order. In total 44
volunteers were included (Table S1) and the IgG response was
measured by bead-based Luminex technology.
doi:10.1371/journal.pone.0029025.g001
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kills blood stage parasites. One month after discontinuation of the
drug, when chloroquine levels were below therapeutic concentra-
tions, the volunteers were challenged with NF54 by mosquito
bites. A progressively reduced incidence and burden of blood stage
parasitemia was measured by PCR during the immunization
phase while there was no evidence of blood stage infection during
the challenge phase [37]. These individuals acquired anti-GLURP
R2 IgG after the first immunization and the antibody levels
decreased after the third immunization. The peak anti-R2 IgG
levels in the immunized group were comparable to the peak levels
among the 44 individuals exposed to one infection (Figure 5). By
contrast the acquisition of anti-PfEMP1 IgG was lower among the
immunized individuals than among the individuals exposed to one
Figure 2. Proportion of malaria naı ¨ve volunteers acquiring IgG against PfEMP1 antigens after controlled experimental P. falciparum
infections. The percentage of malaria infected volunteers with a measurable IgG response against 79 PfEMP1 malaria antigens on day 21 (N=34)
and/or day 35, 42 or 90 (N=30) post infection in descending order. The PfEMP1 domain classification was according to Rask et al [19]. 25 DBL and
CIDR domains were omitted from the figure as there was no IgG recognition of these domains (see Table S2). In total 44 volunteers were included
(Table S1) and the IgG response was measured by bead-based Luminex technology.
doi:10.1371/journal.pone.0029025.g002
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[0;2] (median and 95% confidence interval, CI) domains. Among
the 44 individuals exposed to one infection the number was 1 [CI
0;19] (P=0.02 compared to the immunized individuals). Among
the five individuals serving as controls in the immunization study
the number was 1 [0;2] (P=0.10 compared to the immunized
individuals). Seven of the 10 immunized volunteers did not acquire
IgG against any of the PfEMP1 domains. Figure 6 shows the
reactivity pattern in one of the three volunteers who responded to
PfEMP1 during the study and one who did not. Among the
immunized individuals one acquired IgG to a single RIFIN and
none acquired IgG to the GLURP R0, GLURP R1, MSP3 or
EBA-175 domains.
Discussion
This study was conducted to assess the immune response to
PfEMP1 in experimentally infected individuals. Malaria naı ¨ve
individuals were infected with P. falciparum after bites by
mosquitoes and the infection progressed through the liver, but
was terminated by drug treatment of blood stage parasites after a
few asexual multiplication rounds. Since the PfEMP1 repertoire of
the NF54 parasites used to infect the volunteers is known, and we
had access to recombinant PfEMP1 domains made on basis of
NF54 sequences and domains made on the basis of PfEMP1s from
other parasites, we could assess the acquisition of antibodies
recognizing homologues sequences as well as acquisition of cross
reactive antibodies. Despite the short exposure to asexual blood
stage parasites two thirds of the 44 volunteers acquired PfEMP1
antibodies. The breadth of antibody response varied considerably
between the volunteers. Some only acquired antibodies to one of
the 104 PfEMP1 domains tested while one volunteer acquired
antibodies to 38 domains. We could not establish any association
between the course of infection in the volunteers (parasite load,
maximum parasitemia, number of asexual multiplication cycles)
and the breadth of the PfEMP1 antibody response. Thus the
variation between the individuals may reflect individual differences
in the regulation and induction of immune response between the
individuals or stochastic variation. PfEMP1 can be divided into
group A-C and VAR2CSA. Antibodies were acquired to domains
present in all groups without any particular order or pattern. This
is in agreement with the hypothesis supported by var transcript
Figure 3. Acquisition of IgG to 104 PfEMP1 domains, eight
RIFINs, and GLURP, MSP3, and EBA-175 antigens of Plasmodium
falciparum in malaria naı ¨ve individuals exposed to controlled
experimental P. falciparum infections. The IgG reactivity pattern of
the six groups represented by their acquisition pattern of IgG to blood
stage antigens observed in the 44 examined volunteers after exposure
of a short P. falciparum infection: Volunteers with no acquisition of
antibodies to any of the tested malaria antigens (n=3); volunteers who
acquired antibodies to GLURP only (n=11); and volunteers who
acquired antibodies to 1, 2, 3 or .3 PfEMP1 domains, respectively, as
well as one or more merozoite antigens (n=12, 5, 4 and 9). Results are
expressed as median fluorescent intensity (MFI): Red .2000 MFI; Green
.1000 MFI; Yellow .500 MFI (cut-off value).
doi:10.1371/journal.pone.0029025.g003
Figure 4. Proportion of malaria naı ¨ve volunteers acquiring IgG
against RIFIN antigens after controlled experimental P. falci-
parum infections. The percentage of malaria infected volunteers with
a measurable IgG response against eight RIFIN malaria antigens on day
21 (N=34) and/or day 35, 42 or 90 (N=30) post infection in descending
order. The grouping of RIFINs was according to Wang et al. [45]. V2:
Variable domain 2, the putative extracellular polymorphic region
defined by Cheng et al. [15]. In total 44 volunteers were included
(Table S1) and the IgG response was measured by bead-based Luminex
technology.
doi:10.1371/journal.pone.0029025.g004
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expressed by the parasite population at the onset of the blood stage
infection to maximize the survival in a new host with unknown
immune status [32,46]. The same var transcript analyses also
provided the only formal evidence in support for the hypothesis
that parasites that express a subset of PfEMP1, potentially due to
better cytoadhesion properties, bestow higher parasite growth
rates in naı ¨ve individuals. The PfEMP1 antibody acquisition data
presented here could not verify this hypothesis, probably because
antibody measurements detect the accumulated acquired antibody
repertoire and not directly reflects parasite densities. In 2007,
Elliot et al [47] showed that individuals who had experienced brief
infections during travels in Africa, Asia or the Western Pacific had
acquired IgG recognizing variant surface antigens (VSA) on six
different P. falciparum lines, indicating that IgG against VSA are
broadly cross reactive. In our study, individuals were exposed to
the defined repertoire of PFEMP1 present in NF54. Interestingly,
41% of the volunteers acquired IgG to non-NF54 PFEMP1
domains and two thirds of the 45 non-NF54 PfEMP1 domains were
recognized byatleastone volunteer.Wehave previouslyshown that
there is little cross reactivity between antibodies directed against
PfEMP1 domains produced on a 3D7 genetic background [48].
The present study indicates that even short exposure to a particular
PfEMP1 domain can induce antibodies which react with PfEMP1
domains encoded from different genomes. Combined the studies
suggest that there is little serological cross reactivity between intra-
genomically encoded PfEMP1 and broad cross reactivity between
inter-genomically encoded PfEMP1. This cross reactive PfEMP1
immune response, which cannot in these experiments be explained
by a sequential exposure to PfEMP1 epitopes, could explain why
children in endemic areas relatively quickly generate a broad
repertoire of anti-PfEMP1 antibodies, [26,49]. Such an antibody
response may also enhance the parasites likelihood of establishing a
chronic infection [50].
Figure 5. Acquisition of IgG to GLURP R2 during a liver stage
immunization study. The anti-GLURP R2 IgG levels in 44 volunteers
experimentally infected with Plasmodium falciparum (indicated by a
thick arrow day one) and in 10 volunteers immunized by three
exposures to P. falciparum while treated with chloroquine killing blood
stage parasites (indicated by thin blue arrows day one, 33 and 61) and
after challenge without a drug cover (thick blue arrow day 118). ‘‘35+’’
represents plasma samples taken 35, 42 or 90 days after infection. CHMI:
controlled human malaria infection.
doi:10.1371/journal.pone.0029025.g005
Figure 6. Acquisition of IgG Abs to 104 PfEMP1 domains, eight
RIFINs, and GLURP, MSP3, and EBA-175 antigens in two
immunized volunteers. The two volunteers, 1 and 2, were selected
to represent volunteers with acquisition of antibodies to PfEMP1 and
merozoite antigens (n=3) and volunteers with acquisition of antibodies
to the merozoite antigens only (n=7). The letters A, B, C, D and E
correspond to 32, 60, 116, 151 and 256 days after first immunization.
Parasite challenges were at day 118 [37]. The results are expressed as
median fluorescent intensity (MFI): Red .2000 MFI; Green . 1000 MFI;
Yellow . 500 MFI (cut-off value).
doi:10.1371/journal.pone.0029025.g006
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merozoite antigens and RIFINs. Two thirds of the volunteers
acquired antibodies to the C-terminal R2 repeat region of
GLURP, while only between 0–15% acquired antibodies to
GLURP R0, GLURP R1, MSP3, EBA-175 and the RIFINs. This
is in agreement with a previous observation where no antibodies
were found against a GLURP85–213 long synthetic peptide which
did not include the R2-region [37]. The high recognition of
GLURP R2 could reflect that this region is particularly
immunogenic [51] and/or that the antibodies are induced by
liver parasites expressing GLURP [9]. It has previously been
reported that antibodies to GLURP R2 and other malaria
antigens can be induced by transient exposure to P. falciparum
[52–55].
We also investigated the antibody response in individuals who
were immunized by three exposures to infected mosquito bites
while under chloroquine treatment. Surprisingly, these immunized
individuals were protected, when they receive a fourth exposure to
infected mosquitoes in the absence of chloroquine [37]. During
immunization, the attenuated infections gave raise to brief very
low density blood stage parasiteamia. The question was whether
these brief episodes were sufficient to induce anti-PfEMP1
antibodies, which could mediate protection during challenge.
Our data do not support this hypothesis, since only a few of the
immunized individuals acquired anti-PfEMP1 antibodies to a few
of the domains. Similarly, the immunized individuals did not
acquire antibodies to the most of the other blood stage antigens
tested. The exception was anti-GLURP R2 antibodies, which were
acquired after the first parasite exposure in the immunized
individuals at levels that were similar to those measured in the
non-immunized volunteers. In the immunized individuals, these
antibodies could have been induced by a brief exposure to low
levels of asexual parasites or induced by GLURP or other
glutamine rich proteins expressed by parasites stages in the pre-
erythrocytic life cycle [9].
In conclusion, PfEMP1, RIFIN, GLURP and MSP3 antibodies
are acquired after short controlled P. falciarum infections suggesting
that the immunogenicity of the variant surface antigens is similar
to the less diverse merozoite antigens and broad and strain
transcendent PfEMP1 reactivity may reflect a parasite strategy of
expressing most or all PfEMP1 variants at liver release optimizing
the likelihood of survival and establishment of chronic infections in
the new host.
Supporting Information
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(XLS)
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